Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:public_company
|
| gptkbp:CEO |
gptkb:Tony_J._Hunt
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:CUSIP |
759916109
|
| gptkbp:foundedYear |
1981
|
| gptkbp:headquartersLocation |
gptkb:Waltham,_Massachusetts,_United_States
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:ISIN |
US7599161095
|
| gptkbp:marketCap |
multi-billion USD (as of 2024)
|
| gptkbp:name |
gptkb:Repligen_Corporation
|
| gptkbp:numberOfEmployees |
over 1,000 (as of 2024)
|
| gptkbp:products |
filtration systems
chromatography resins protein A ligands bioprocessing technologies |
| gptkbp:stockExchange |
gptkb:Russell_2000
gptkb:S&P_400 |
| gptkbp:stockSymbol |
RGEN
|
| gptkbp:tradedOn |
gptkb:NASDAQ
|
| gptkbp:website |
https://www.repligen.com/
|
| gptkbp:bfsParent |
gptkb:Repligen_Corporation
|
| gptkbp:bfsLayer |
8
|
| http://www.w3.org/2000/01/rdf-schema#label |
NASDAQ:RGEN
|